RT Journal Article
SR Electronic
T1 Genetically proxied inhibition of L-2-hydroxyglutarate dehydrogenase and the risk of coronary artery disease: A Mendelian randomization study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.15.23284550
DO 10.1101/2023.01.15.23284550
A1 Song, Euijun
YR 2023
UL http://medrxiv.org/content/early/2023/02/09/2023.01.15.23284550.abstract
AB Background L-2-hydroxyglutarate dehydrogenase (L2HGDH) deletion-induced L-2-hydroxyglutarate accumulation plays a cardioprotective role in hypoxic conditions. However, there has been no causal evidence in real-world clinical data. We aimed to examine the causal effects of L2HGDH inhibition on coronary artery disease (CAD) and myocardial infarction (MI) using Mendelian randomization (MR) analysis.Methods We used nine L2HGDH-proxied genetic variants associated with blood 2-hydroxyglutarate levels as genetic instruments, and performed two-sample MR analysis using the CARDIoGRAMplusC4D meta-analysis datasets of CAD (60,801 CAD cases and 123,504 controls) and MI (34,541 MI cases and 261,984 controls).Results Genetically proxied inhibition of L2HGDH associated with 2-hydroxyglutarate levels potentially decreased the risk of CAD (odds ratio [OR] 0.486, 95% confidence interval [CI] 0.242–0.977, P=0.043) but was not associated with the risk of MI (OR 0.676, 95% CI 0.312–1.463, P=0.320). This potentially causal association between L2HGDH inhibition and CAD was unlikely to be biased by horizontal pleiotropy, whereas there might be a weak instrument bias.Conclusion Our MR analysis suggests the potential association between genetically proxied inhibition of L2HGDH and CAD. Our findings may have therapeutic implications for L2HGDH inhibitors in CAD, and further large-scale clinical studies are needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used only publicly available GWAS summary statistics datasets.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.